Toltrazuril is an antiprotozoal drug used to treat coccidiosis and other parasitic infections in dogs. It works by killing the single-celled parasites that cause watery, sometimes bloody diarrhea, particularly in puppies and dogs living in shelters or kennels. While widely used in veterinary medicine for livestock and approved for dogs in some countries, toltrazuril is not FDA-approved for use in dogs in the United States, meaning veterinarians prescribe it on an extra-label basis.
How Toltrazuril Works
Toltrazuril belongs to a class of drugs called triazines. It targets a unique structure inside the parasite’s cells called the apicoplast, a small organelle that runs essential biochemical pathways the parasite needs to survive. By disrupting these pathways, possibly by blocking certain metabolic enzymes or interfering with the parasite’s ability to build DNA components, toltrazuril doesn’t just slow the infection down. It kills the parasites outright. In pharmacology terms, this makes it “cidal” rather than “static,” which is a meaningful distinction: a cidal drug eliminates the organisms rather than simply stopping them from multiplying and waiting for the immune system to clean up.
This killing action is one reason toltrazuril is favored in high-infection environments like breeding facilities. A single dose can dramatically reduce the parasite burden, breaking the cycle of contamination in shared living spaces.
What Infections It Treats
Toltrazuril has specific activity against apicomplexan parasites, a large family of single-celled organisms that invade and reproduce inside the cells lining a dog’s intestines. The most common target is coccidia, specifically species in the genus Isospora (sometimes called Cystoisospora), which cause coccidiosis. Coccidiosis is especially prevalent in puppies, who pick up the parasites from contaminated environments and haven’t yet developed immune resistance.
Beyond coccidia, toltrazuril shows activity against Neospora caninum, a parasite that can cause neuromuscular disease in dogs. Laboratory studies have confirmed that toltrazuril inhibits Neospora replication, and in animal models, treatment reduced both fetal loss and the parasite’s ability to pass from mother to offspring during pregnancy. This makes it a potential tool for managing neosporosis in breeding dogs, though its use for this purpose is less established than its use for coccidiosis.
Signs of Coccidiosis in Dogs
Coccidiosis ranges from completely silent to severe, depending on the dog’s age, immune status, and parasite load. Many adult dogs carry coccidia without ever showing symptoms. Puppies and immunocompromised dogs are the ones who get sick.
The hallmark sign is watery diarrhea, which can progress to bloody or mucus-filled stool. Puppies may also show poor appetite, dehydration, lethargy, and weight loss. In very young or heavily infected puppies, untreated coccidiosis can be life-threatening. The infection is diagnosed through a fecal examination, where the parasite’s egg-like structures (oocysts) are visible under a microscope.
How Toltrazuril Compares to Other Treatments
The traditional treatment for coccidiosis in dogs is sulfadimethoxine, a sulfonamide antibiotic sold under the brand name Albon. It’s the only FDA-approved option for canine coccidiosis in the U.S., but it has drawbacks. Treatment typically lasts one to three weeks, requiring daily dosing until several days after symptoms resolve. Sulfadimethoxine is also considered coccidiostatic rather than coccidiocidal, meaning it stops the parasites from reproducing but doesn’t kill them directly. The dog’s immune system has to finish the job, which can be a problem in very young puppies whose immune defenses are still developing.
Toltrazuril, by contrast, is often effective as a single oral dose or a short course of treatment. Its cidal action means it doesn’t rely as heavily on the dog’s immune response. Ponazuril, which is actually the active metabolite that toltrazuril converts into inside the body, is sometimes used as an alternative, typically dosed over two to five days. Both toltrazuril and ponazuril are used extra-label in dogs in the U.S. and most other countries.
For kennel and shelter settings where coccidiosis spreads quickly through contaminated feces, the convenience of a single-dose treatment that actually kills the parasites makes toltrazuril particularly practical. It reduces environmental contamination faster than a multi-week course of sulfadimethoxine.
Dosing and Administration
Toltrazuril is given orally, usually as a liquid suspension. While no standardized canine dose exists in the U.S. due to the lack of FDA approval, veterinarians commonly follow protocols derived from livestock dosing and published veterinary literature. In food animals like piglets, calves, and lambs, the standard dose is 15 to 20 mg per kilogram of body weight given as a single oral dose. Canine dosing typically falls in a similar range, though your veterinarian will determine the exact amount based on the severity of infection, the dog’s size, and whether a repeat dose is needed.
Some veterinarians prescribe a single dose with a follow-up dose one to two weeks later to catch any parasites that were in earlier, less vulnerable life stages during the first treatment. The timing matters because toltrazuril is most effective against parasites during their intracellular replication phase.
Safety and Use in Puppies
Toltrazuril has a relatively wide safety margin. In Europe, where a combination product containing toltrazuril is approved for dogs (marketed as Procox), the labeled guidelines allow use in puppies as young as two weeks old, provided they weigh at least 0.4 kilograms (just under one pound). Puppies younger than two weeks or lighter than that threshold should not receive it.
Side effects are uncommon at standard doses. Mild, short-lived digestive upset is the most frequently reported issue. Because the drug is metabolized by the liver, dogs with significant liver disease may need closer monitoring. Pregnant dogs represent another area of caution: while the Neospora research suggests potential benefits during pregnancy, the safety data in pregnant dogs is limited, and the decision to treat should be made carefully.
Regulatory Status in the U.S.
Toltrazuril is not FDA-approved for any animal species in the United States. It is approved in other countries, including in the European Union for use in dogs (as part of a combination product) and widely across the world for use in livestock. In the U.S., the FDA has actively issued warning letters to companies selling toltrazuril products online without approval, including enforcement actions as recent as May 2024.
This means the toltrazuril products you might find sold online in the U.S. are unregulated. Their concentration, purity, and safety are not guaranteed. If your dog needs toltrazuril, the safest route is through a veterinarian who can either prescribe a compounded formulation from a licensed pharmacy or use a related approved product like ponazuril off-label. Buying unregulated animal drugs online carries real risks, including incorrect concentrations that could underdose (leaving the infection untreated) or overdose your dog.